Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics
Antioxidants · 10.02.2023 · 12 (2) · 444
DOI: 10.3390/antiox12020444 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 10.02.2023. Verfasst von Darya Bulbiankova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universitas Miguel Hernández (UMH), 03202 Elche, Spain. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Generalitat Valenciana, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Aging is a complex process characterized by an ongoing decline in physiological functions, leading to degenerative diseases and an increased probability of death. Cellular senescence has been typically considered as an anti-proliferative process; however, the chronic accumulation of senescent cells contributes to tissue dysfunction and aging. In this review, we discuss some of the most important hallmarks and biomarkers of cellular senescence with a special focus on skin biomarkers, reactive oxygen species (ROS), and senotherapeutic strategies to eliminate or prevent senescence. Although most of them are not exclusive to senescence, the expression of the senescence-associated beta-galactosidase (SA-β-gal) enzyme seems to be the most reliable biomarker for distinguishing senescent cells from those arrested in the cell cycle. The presence of a stable DNA damage response (DDR) and the accumulation of senescence-associated secretory phenotype (SASP) mediators and ROS are the most representative hallmarks for senescence. Senotherapeutics based on natural compounds such as quercetin, naringenin, and apigenin have shown promising results regarding SASP reduction. These compounds seem to prevent the accumulation of senescent cells, most likely through the inhibition of pro-survival signaling pathways. Although studies are still required to verify their short- and long-term effects, these therapies may be an effective strategy for skin aging.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Research, Development and Innovation in Health Biotechnology of Elche (IDiBE), Universitas Miguel Hernández (UMH), 03202 Elche, Spain.
- Institute of Sanitary and Biomedical Research of Alicante (ISABIAL), 03010 Alicante, Spain.
- CIBER, Fisiopatología de la Obesidad y la Nutrición, CIBERobn, Instituto de Salud Carlos III (CB12/03/30038), 28029 Madrid, Spain.
ORCID-Profile: Rocío Díaz-Puertas, Francisco Javier Álvarez-Martínez, María Herranz-López, Enrique Barrajón-Catalán, Vicente Micol
Förderung
- Ministerio de Ciencia e Innovación
- Generalitat Valenciana
- Instituto de Salud Carlos III
- European Union
- Spanish Ministry of Science and Innovation
- the Official Funding Agency for Biomedical Research of the Spanish Government, Institute of Health Carlos III (ISCIII) through CIBEROBN
- Agencia Valenciana de la Innovación
- Requalification of the Spanish University System
Zitieren
APA
Bulbiankova, D., Díaz-Puertas, R., Álvarez-Martínez, F. J., Herranz-López, M., Barrajón-Catalán, E., & Micol, V. (2023). Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics. Antioxidants, 12(2), 444. https://doi.org/10.3390/antiox12020444
Vancouver
Bulbiankova D, Díaz-Puertas R, Álvarez-Martínez FJ, Herranz-López M, Barrajón-Catalán E, Micol V. Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics. Antioxidants. 2023;12(2):444. doi:10.3390/antiox12020444
BibTeX
@article{Bulbiankova2023,
author = {Bulbiankova, Darya and Díaz-Puertas, Rocío and Álvarez-Martínez, Francisco Javier and Herranz-López, María and Barrajón-Catalán, Enrique and Micol, Vicente},
title = {Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {2},
pages = {444},
doi = {10.3390/antiox12020444}
}
EUVIMED